Advocacy intelligence hub — real-time data for patient organizations
Wilate: FDA approved
Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Wilate
Octapharma USA, Inc.
Wilate
(von Willebrand Factor/Coagulation Factor VIII Complex (Human))Orphan drugOctapharma USA, Inc.
Browse all Hematological disease associated with an acquired peripheral neuropathy news →
View all Hematological disease associated with an acquired peripheral neuropathy specialists →